Results 181 to 190 of about 89,572 (287)

Non‐Cancer Causes of Death in Patients With Metastatic Hormone‐Sensitive Prostate Cancer: A Real‐World Analysis

The Prostate, Volume 86, Issue 10, Page 1170-1173, July 2026.
ABSTRACT Background As overall survival improves in metastatic hormone‐sensitive prostate cancer (mHSPC), non‐cancer causes of death are increasingly relevant. Methods We conducted a real‐world multicenter study of patients diagnosed with mHSPC treated with ADT alone or in combination. Causes of death before progression to castration‐resistant prostate
Marta Garcia de Herreros, Clara Rodrigo, Laura Ferrer‐Mileo, Laia Fernández‐Mañas, Joel Mases, Nely Diaz, Antoni Vilaseca, Mariana Altamirano, Roser Gibanel, Maria José Ribal, Natalia Jimenez, Oscar Reig, Mariona Figols, Miguel Ángel Climent, Albert Font, Begoña Mellado   +15 more
wiley   +1 more source

Inhibition of PTCH1 drug efflux activity enhances chemotherapy efficacy against triple negative breast cancers. [PDF]

Transl Oncol
Cogoluegnes S, Kovachka S, Dubois T, Würth R, Donato E, Trumpp A, Franco M, Luton F, Azoulay S, Mus-Veteau I.   +9 more
europepmc   +1 more source

Rezvilutamide plus docetaxel in chemotherapy-naive metastatic castration-resistant prostate cancer patients after progression on abiraterone: A multi-centre, open-label, phase II trial. [PDF]

Clin Transl Med
Liu Z, Chen B, Dai T, Jiang S, Luo H, Liao H, Yu D, Chen Z, Zhang D, Li Z, Zhang Z, Bai H, Liu F, Lin J, Wang Y, Feng P, Wei Q.   +16 more
europepmc   +1 more source

Evaluation of Red Blood Cell Biomechanics in the Setting of Cancer‐Associated Anemia and Chemotherapy

Microcirculation, Volume 33, Issue 5, July 2026.
ABSTRACT Introduction Red blood cells (RBCs) possess distinct biomechanical properties that enable their survival and efficient oxygen delivery. Cancer‐associated anemia, frequently compounded by chemotherapy, is a major clinical challenge, yet little is known about how RBC biomechanics contribute to its pathophysiology.
Deirdre Finnigan, Nick Cruickshanks, George Ilbawi, Regan Bucciol, Yousra Tera, Maha Othman   +5 more
wiley   +1 more source

Risk Factors and Clinical Significance of Grade ≥3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer. [PDF]

In Vivo
Sato R, Yoshimi Y, Nishio T, Matsunaga YU, Matsumoto R.   +4 more
europepmc   +1 more source

Pegargiminase Suppresses the Fanconi Anemia Pathway and Promotes Melphalan‐Induced DNA Double‐Strand Breaks in Uveal Melanoma

Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
ADI‐PEG20 enhances melphalan‐induced DNA DSBs in UM cells. We describe potentiation of DNA DSBs in UM cell lines upon treatment with ADI‐PEG20 and melphalan (92.1 cells with STRIDE by intoDNA). ADI‐PEG20 suppresses multiple members of the FA pathway—a known resistance mechanism for melphalan—providing a rationale for exploring this drug combination in ...
Iuliia Pavlyk, George Field, Matthew Young, Josephine Carpentier, Emilia A. Szlosarek, Michaela R. O'Keeffe‐Brown, Timothy Crook, Nelofer Syed, John S. Bomalaski, Pui Ying Chan, Peter W. Szlosarek   +10 more
wiley   +1 more source

Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer. [PDF]

J Immunother Precis Oncol
Castro EA, Jani YC, Bilen MA.
europepmc   +1 more source

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost, Olayinka Okeleji, Amr Elgehiny, Douglas Harrison, Cynthia Herzog, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Dristhi Ragoonanan, Yago Nieto, Irtiza N. Sheikh   +10 more
wiley   +1 more source

Chemotherapy in combination with KRAS inhibitors in <i>KRAS</i>-mutated non-small cell lung cancer. [PDF]

J Thorac Dis
Rosell R, González-Cao M.
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, Volume 20, Issue 6, Page 1626-1642, June 2026.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source